OKYO Pharma
OKYO
7 hedge funds and large institutions have $1.54M invested in OKYO Pharma in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
774% more capital invested
Capital invested by funds: $176K → $1.54M (+$1.36M)
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
2.28% more ownership
Funds ownership: 0.34% → 2.61% (+2.3%)
0% more funds holding
Funds holding: 7 → 7 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$1.29M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$61.1K |
| 3 |
Morgan Stanley
New York
|
+$24.3K |
| 4 |
Cerity Partners
New York
|
+$21.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$29.5K |
| 2 |
Renaissance Technologies
New York
|
-$7.98K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$176 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Barclays
London,
United Kingdom
| $1.34M | +$1.29M | +733,333 | +2,933% |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $61.9K | +$61.1K | +34,784 | New |
|
|
3
Morgan Stanley
New York
| $49K | +$24.3K | +13,846 | +100% |
|
|
4
Cerity Partners
New York
| $21.8K | +$21.6K | +12,312 | New |
|
5
Geode Capital Management
Boston,
Massachusetts
| $21.5K | – | – | – |
|
|
6
Renaissance Technologies
New York
| $21K | -$7.98K | -4,547 | -28% |
|
7
HSBC Holdings
London,
United Kingdom
| $20.3K | – | – | – |
|
|
8
Citadel Advisors
Miami,
Florida
| – | -$29.5K | -15,943 | Closed |
|
|
9
UBS Group
Zurich,
Switzerland
| – | -$176 | -95 | Closed |
|
OKYO Hedge Fund Activity: Q4 2023 in Review
7 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in OKYO Pharma (OKYO) for Q4 2023, worth a combined $1.54M — up 774% from $176K a quarter earlier.
Fund positioning in OKYO was balanced in Q4 2023: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 1 trimmed.
The largest buyer was Barclays, adding an estimated $1.29M. The largest seller was Citadel Advisors, exiting entirely with an estimated $29.5K sold.
- 7 institutional investors held OKYO Pharma (OKYO) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $1.54M of OKYO Pharma stock for Q4 2023, up 774% quarter-over-quarter.
- 2 funds opened new OKYO Pharma positions in Q4 2023 and 2 closed out, a net change of 0 holders.
- The largest OKYO Pharma buyer in Q4 2023 was Barclays, an estimated $1.29M added.
- The largest OKYO Pharma seller in Q4 2023 was Citadel Advisors, an estimated $29.5K sold.
Based on aggregated 13F filings for Q4 2023.